Tag Archive for: non-small cell lung cancer

The full results, presented at the annual American Society of Clinical Oncology meeting in Chicago and published in the Journal of Clinical Oncology, show that Trodelvy reduced the risk of death by 16%, with similar improvement for harder-to-treat squamous and non-squamous types of NSCLC.

AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.

Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III NSCLC trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb.

The financing was secured from life sciences investment company Abingworth and will help Gilead run “select clinical studies” of Trodelvy.

The U.S. Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics’ lung cancer therapy trial after a patient death, the company said on Wednesday.

The company announced that its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study.

At this year’s European Society for Medical Oncology, excitement topped 2022 levels on NSCLC and breast cancer innovation.

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

When given concurrently with chemoradiotherapy, AstraZeneca’s Imfinzi in a late-stage lung cancer study did not lead to significant improvements in progression-free survival versus chemoradiotherapy alone.

MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets, and BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.